Avesthagen Limited has yet again established its position as a leader in the successful application of next gen technologies as it announces the completion of the first Parsi breast cancer whole genome sequence of a 74-year-old Parsi woman with a heritable form of breast cancer. The incidence of breast cancer in most populations is strongly linked to a genetic basis but little is known about the variants at the present time. By employing whole-genome sequencing of affected individuals all genetic variants linked to the disease can be identified. This will lead to a broader understanding of breast cancer disease mechanisms, the development of new diagnostic tests, and the discovery of new drug targets and design of drugs.